Statins for primary prevention of venous thromboembolism

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study

“…In this regard, “maintenance of ideal cardiovascular health” is associated with lower D-dimer [19] and reduced VTE incidence [21, 22], and may be one strategy to reduce the large public health burden of VTE. Use of statins also can lower D-dimer [23] but whether they reduce VTE remains controversial [24]. …”

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study

“…In this regard, “maintenance of ideal cardiovascular health” is associated with lower D-dimer [19] and reduced VTE incidence [21, 22], and may be one strategy to reduce the large public health burden of VTE. Use of statins also can lower D-dimer [23] but whether they reduce VTE remains controversial [24]. …”

Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications

“…During a median follow-up of 1.9 years, the authors found a statistically significant reduction in the risk of VTE in the rosuvastatin group compared to the placebo group (HR of 0.57, 95% CI of 0.37 to 0.86) [ 115 ]. However, a recent meta-analysis of 27 studies including 122,601 patients found that using statins for primary prevention may slightly reduce the incidence of VTE (OR of 0.86, 95% CI of 0.76–0.98), although this effect is likely too weak to be considered significant [ 116 ]. Thus, RCTs specifically designed to evaluate the potential benefits of statins in the primary prevention of VTE are still needed.…”

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study

“…In this regard, “maintenance of ideal cardiovascular health” is associated with lower D-dimer [19] and reduced VTE incidence [21, 22], and may be one strategy to reduce the large public health burden of VTE. Use of statins also can lower D-dimer [23] but whether they reduce VTE remains controversial [24]. …”

Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications

“…During a median follow-up of 1.9 years, the authors found a statistically significant reduction in the risk of VTE in the rosuvastatin group compared to the placebo group (HR of 0.57, 95% CI of 0.37 to 0.86) [ 115 ]. However, a recent meta-analysis of 27 studies including 122,601 patients found that using statins for primary prevention may slightly reduce the incidence of VTE (OR of 0.86, 95% CI of 0.76–0.98), although this effect is likely too weak to be considered significant [ 116 ]. Thus, RCTs specifically designed to evaluate the potential benefits of statins in the primary prevention of VTE are still needed.…”

Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study

“…In this regard, “maintenance of ideal cardiovascular health” is associated with lower D-dimer [19] and reduced VTE incidence [21, 22], and may be one strategy to reduce the large public health burden of VTE. Use of statins also can lower D-dimer [23] but whether they reduce VTE remains controversial [24]. …”

Statins as an Adjunctive Antithrombotic Agent in Thrombotic Antiphospholipid Syndrome: Mechanisms and Clinical Implications

“…During a median follow-up of 1.9 years, the authors found a statistically significant reduction in the risk of VTE in the rosuvastatin group compared to the placebo group (HR of 0.57, 95% CI of 0.37 to 0.86) [ 115 ]. However, a recent meta-analysis of 27 studies including 122,601 patients found that using statins for primary prevention may slightly reduce the incidence of VTE (OR of 0.86, 95% CI of 0.76–0.98), although this effect is likely too weak to be considered significant [ 116 ]. Thus, RCTs specifically designed to evaluate the potential benefits of statins in the primary prevention of VTE are still needed.…”